

Ref. No. CTL/SAST/26-27/00050/02

01 July 2026

1. **Department of Corporate Services,**
BSE Limited
Floor 25, P J Towers,
Dalal Street,
Mumbai - 400 001
2. **National Stock Exchange of India Limited**
Exchange Plaza,
Bandra Kurla Complex, Bandra (E),
Mumbai - 400 051
3. **Gujarat Themis Biosyn Limited**
Plot No 69-C, GIDC Industrial Estate,
Valsad District, Vapi, Gujarat, India, 396195

Sub: Disclosure under Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Dear Sir/ Ma'am,

Enclosed is a disclosure made by CTL Trusteeship Limited under Regulation 29 (1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (the "**Takeover Code**").

A debenture trust deed dated June 25, 2026, as amended from time to time ("**Debenture Trust Deed**") has been entered into between, *inter alia*, OSS Software Solutions Labs Private Limited (*as issuer*) ("**Issuer**") and CTL Trusteeship Limited ("**Debenture Trustee**") for the purpose of issuance of debentures by the Issuer ("**Debentures**").

Pharmaceutical Business Group (India) Limited ("**PBGIL**") holds 5,12,40,000 equity shares, constituting 47.02% of the issued and paid-up share capital as well as the total diluted share/ voting capital of Gujarat Themis Biosyn Limited ("**Target Company**"). Vividhmargi Investments Private Limited ("**VIPL**") holds 49,49,500 equity shares in PBGIL, constituting 98.988% of the issued and paid-up share capital of PBGIL.

In connection with the Debentures, the following encumbrances have been created by VIPL over the following shares of PBGIL, in favor of the Debenture Trustee, thereby resulting in an indirect encumbrance over shares of the Target Company:

- (a) pledge over 25,24,245 equity shares, constituting 51% of the issued and paid-up share capital as well as the total diluted share/ voting capital of PBGIL, with effect from June 29, 2026 ("**Pledged Shares**"); and
- (b) non-disposal undertaking over 21,57,855 equity shares, constituting 47.988% of the issued and paid-up share capital as well as the total diluted share/ voting capital of PBGIL.

(collectively, "**Shares**")

This disclosure is being made by the Debenture Trustee in relation to the creation of indirect encumbrance by VIPL over the shares of the Target Company on account of creation of encumbrance (by way of pledge and non-disposal undertaking) over the Shares of PBGIL.

Yours faithfully,

For CTL Trusteeship Limited

Authorised Signatory

Name: Deesha Srikanth

Designation: Senior Vice President

Place: Mumbai

Date: 01 July 2026

Disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A - Details of the Acquisition

Name of the Target Company (TC)	Gujarat Themis Biosyn Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	CTL Trusteeship Limited acting in its capacity as the debenture trustee under the Debenture Trust Deed (<i>defined below</i>)		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited and National Stock Exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:	Refer to Note below	Refer to Note below	Refer to Note below
(a) Shares carrying voting rights			
(b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	Refer to Note below	Refer to Note below	Refer to Note below
(c) Voting rights (VR) otherwise than by equity shares	Refer to Note below	Refer to Note below	Refer to Note below
(d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Refer to Note below	Refer to Note below	Refer to Note below
(e) Total (a+b+c+d)	Refer to Note below	Refer to Note below	Refer to Note below
Details of acquisition	Refer to Note below	Refer to Note below	Refer to Note below
(a) Shares carrying voting rights acquired			

CTL Trusteeship Limited (Formerly known as "CTL Trusteeship Private Limited" & "Catalyst Family Office and Corporate Adviser Private Limited")

Registered Office: GDA House, First Floor, Plot No. 85 S. No. 94 & 95, Bhusari Colony (Right), Kothrud, Pune, Maharashtra, Pune - 411 038
Delhi Office: 910-911, 9th Floor, Kailash Building, 26 Kasturba Gandhi Marg, New Delhi-110 001 **Tel:** +91 (11) 4302 9101/02
Corporate Office: 901, 9th Floor, Tower-B, Peninsula Business Park, Senapati Bapat Marg, Lower Parel (W), Mumbai - 400013
Tel: +91 (22) 4922 0555 | **Fax:** +91 (22) 4922 0505
CIN No. U66190PN2024PLC237102 | **Email:** cti@ctltrustee.com | **Website:** www.ctltrustee.com
Pune | Mumbai | Bengaluru | Delhi | Chennai | Ahmedabad | Kolkata | Hyderabad

(b)	VRs acquired otherwise than by equity shares	Refer to Note below	Refer to Note below	Refer to Note below
(c)	Warrants acquired by way of encumbrance [#]	Refer to Note below	Refer to Note below	Refer to Note below
(d)	Shares in the nature of encumbrance (pledge/ lien/non disposal undertaking/others)	Refer to Note below	Refer to Note below	Refer to Note below
(e)	Total (a+b+c+/-d)	Refer to Note below	Refer to Note below	Refer to Note below
After the acquisition, holding of acquirer along with PACs of:				
(a)	Shares carrying voting rights	Refer to Note below	Refer to Note below	Refer to Note below
(b)	VRs otherwise than by equity shares	Refer to Note below	Refer to Note below	Refer to Note below
(c)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition in the nature of encumbrance[#]	Refer to Note below	Refer to Note below	Refer to Note below
(d)	Shares in the nature of encumbrance (pledge/ lien /non disposal undertaking/ others)	Refer to Note below	Refer to Note below	Refer to Note below
(e)	Total (a+b+c+d)	Refer to Note below	Refer to Note below	Refer to Note below
Mode of acquisition (e.g. open market/public issue/rights issue/preferential allotment/inter se transfer/encumbrance, etc.)		There is no acquisition of any shares of the Target Company at present. This disclosure is being made considering creation of encumbrance (by way of pledge and non-disposal undertaking) over the Shares, which may result in an indirect encumbrance on shares of Target.		
Salient features of the securities acquired including time till		Not applicable		

redemption, ratio at which it can be converted into equity shares, etc.	
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/ any other instrument that entitles the acquirer to receive shares in the TC.	In relation to encumbrance by way of: (a) pledge over 25,24,245 equity shares, constituting 51% of the issued and paid-up share capital as well as the total diluted share/ voting capital of PBGIL - June 29, 2026; and (b) non-disposal undertaking over 21,57,855 equity shares, constituting 47.988% of the issued and paid-up share capital as well as the total diluted share/ voting capital of PBGIL.
Equity share capital / total voting capital of the TC before the said acquisition	INR 10,89,65,265, comprising of 10,89,65,265 fully paid-up equity shares of INR 1/- each
Equity share capital/ total voting capital of the TC after the said acquisition	INR 10,89,65,265, comprising of 10,89,65,265 fully paid-up equity shares of INR 1/- each
Total diluted share/voting capital of the TC after the said acquisition	INR 10,89,65,265, comprising of 10,89,65,265 fully paid-up equity shares of INR 1/- each

Note #-

1. Pharmaceutical Business Group (India) Limited (“**PBGIL**”) holds 5,12,40,000 equity shares, constituting 47.02% of the issued and paid-up share capital as well as the total diluted share/ voting capital of Gujarat Themis Biosyn Limited (“**Target Company**”). Vividhmargi Investments Private Limited (“**VIPL**”) holds 49,49,500 equity shares in PBGIL, constituting 98.988% of the issued and paid-up share capital of PBGIL.
2. A debenture trust deed dated June 25, 2026, as amended from time to time (“**Debenture Trust Deed**”) has been entered into between, *inter alia*, OSS Software Solutions Labs Private Limited (*as issuer*) (“**Issuer**”) and CTL Trusteeship Limited (“**Debenture Trustee**”) for the purpose of issuance of debentures by the Issuer (“**Debentures**”).
3. In connection with the Debentures, the following encumbrances have been created by VIPL over the following shares of PBGIL, pursuant to a Pledge Agreement cum Non-Disposal Undertaking dated June 28, 2026, in favor of the Debenture Trustee, thereby resulting in an indirect encumbrance over shares of the Target Company –
 - (a) pledge over 25,24,245 equity shares, constituting 51% of the issued and paid-up share capital as well as the total diluted share/ voting capital of PBGIL, with effect from June 29, 2026 (“**Pledged Shares**”); and
 - (b) hold over 21,57,855 equity shares, constituting 47.988% of the issued and paid-up share capital as well as the total diluted share/ voting capital of PBGIL.

(collectively, “**Shares**”)

4. In terms of Regulation 29 (1) read with Regulation 29 (4) of the Takeover Code, encumbrance over shares shall be treated as an acquisition. Accordingly, this disclosure is being made in respect of the encumbrance created over the Shares (as described in note#3 above), thereby resulting in an indirect encumbrance over shares of the Target Company in favour of the Debenture Trustee.
5. This disclosure is being made by the Debenture Trustee in relation to the creation of indirect encumbrance by VIPL over the shares of the Target Company on account of creation of encumbrance (by way of pledge and non-disposal undertaking) over the Shares of PBGIL.

For CTL Trusteeship Limited

Authorised Signatory

Name: Deesha Srikkanth

Designation: Senior Vice President

Place: Mumbai

Date: 01 July 2026

Part-B***

Name of the Target Company: Gujarat Themis Biosyn Limited

Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquirer and/ or PACs
CTL Trusteeship Limited acting in its capacity as the debenture trustee under the Debenture Trust Deed.	No	

For CTL Trusteeship Limited

Authorised Signatory

Name: Deesha Srikanth

Designation: Senior Vice President

Place: Mumbai

Date: 01 July 2026

Note:

- (*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement and under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as per the shareholding pattern for the quarter ended March 31, 2026, as publicly disclosed by the Target Company.
- (**) Diluted share/voting capital means the total number of shares in the Target Company assuming full conversion of the outstanding convertible securities/warrants into equity shares of the Target Company.
- (***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.